Skip to main content
Springer Nature Link
Account
Fig. 7 | Clinical Pharmacokinetics

Fig. 7

From: Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

Fig. 7

Estimation of inotuzumab ozogamicin exposure in pediatric patients with B-cell precursor acute lymphoblastic leukemia using the final model and dosing record in the trial. (a) Cumulative area under the concentration–time curve (AUC) at the end of cycle 1 for non-responders and responders. (b) Cumulative AUC at the end of each cycle 1 for minimal residual disease (MRD)-positive and MRD-negative patients

Back to article page